Supercomputer-based Bayesian approach to AI pays dividends for BPGbio

In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery. The company crunches trillions of data points per patient. “It’s massive, which is why we use a supercomputer,” said Niven R. Narain, Ph.D., BPGbio CEO. The company has an exclusive relationship with Oak Ridge National Labs, using its Frontier supercomputer to perform complex computational tasks, including the analysis of multi-omics data, the development of predictive models, and the simulation of biological systems. Frontier is hailed as the world’s first exascale supercomputer, meaning it can perform more than 1 quintillion calculations per second.

BPGbio’s AI-powered platform, known as NAi Interrogative Biology, illustrates its approach to drug and diagnostic discovery. The platform includes a lmassive biobank of multi-omi…

Read more
  • 0